Cliff Asness's RNA Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 172,235 shares of Atrium Therapeutics, Inc. (RNA) worth $2.32 M, representing 0.00% of the portfolio. First purchased in 2024-Q2, this short-term holding has been held for 8 quarters.
Based on 13F filings, Cliff Asness has maintained this position in RNA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 172,235 shares. Largest reduction occurred in Q1 2026, reducing 14,149 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Atrium Therapeutics (RNA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Atrium Therapeutics (RNA) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +172,235 | New Buy | 172,235 | $13.45 |
| Q1 2026 | -14,149 | Sold Out | 0 | $0.00 |
| Q4 2025 | +14,149 | New Buy | 14,149 | $72.13 |
| Q2 2025 | -10,785 | Sold Out | 0 | $0.00 |
| Q1 2025 | -2,276 | Reduce 17.43% | 10,785 | $29.52 |
| Q4 2024 | -11,892 | Reduce 47.66% | 13,061 | $29.08 |
| Q3 2024 | +12,911 | Add 107.22% | 24,953 | $45.93 |
| Q2 2024 | +12,042 | New Buy | 12,042 | $40.85 |
Cliff Asness's Atrium Therapeutics Investment FAQs
Cliff Asness first purchased Atrium Therapeutics, Inc. (RNA) in Q2 2024, acquiring 12,042 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Atrium Therapeutics, Inc. (RNA) for 8 quarters since Q2 2024.
Cliff Asness's largest addition to Atrium Therapeutics, Inc. (RNA) was in Q2 2026, adding 172,235 shares worth $2.32 M.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 172,235 shares of Atrium Therapeutics, Inc. (RNA), valued at approximately $2.32 M.
As of the Q2 2026 filing, Atrium Therapeutics, Inc. (RNA) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Atrium Therapeutics, Inc. (RNA) was 172,235 shares, as reported at the end of Q2 2026.